A detailed history of Northern Trust Corp transactions in Silverback Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 452,380 shares of SBTX stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
452,380
Previous 267,571 69.07%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
N/A
184,809 Added 69.07%
452,380 $0
Q2 2024

Aug 14, 2024

BUY
N/A
5,462 Added 2.08%
267,571 $0
Q1 2024

May 14, 2024

BUY
N/A
2,428 Added 0.93%
262,109 $0
Q4 2023

Feb 13, 2024

SELL
N/A
-1,459 Reduced 0.56%
259,681 $0
Q3 2023

Nov 13, 2023

BUY
N/A
30,449 Added 13.2%
261,140 $0
Q2 2023

Aug 11, 2023

BUY
N/A
158,721 Added 220.54%
230,691 $0
Q1 2023

May 15, 2023

BUY
N/A
4,667 Added 6.93%
71,970 $0
Q4 2022

Feb 13, 2023

BUY
$0.0 - $6.07 $0 - $170,075
28,019 Added 71.32%
67,303 $0
Q3 2022

Nov 14, 2022

BUY
$3.91 - $5.52 $7,913 - $11,172
2,024 Added 5.43%
39,284 $207,000
Q2 2022

Aug 12, 2022

SELL
$2.9 - $4.44 $395,296 - $605,211
-136,309 Reduced 78.53%
37,260 $158,000
Q1 2022

May 13, 2022

SELL
$3.51 - $6.74 $22,074 - $42,387
-6,289 Reduced 3.5%
173,569 $609,000
Q4 2021

Feb 08, 2022

SELL
$6.03 - $11.67 $35,510 - $68,724
-5,889 Reduced 3.17%
179,858 $1.2 Million
Q3 2021

Nov 15, 2021

BUY
$9.98 - $35.22 $597,293 - $2.11 Million
59,849 Added 47.54%
185,747 $1.85 Million
Q2 2021

Aug 13, 2021

SELL
$24.71 - $44.28 $214,631 - $384,616
-8,686 Reduced 6.45%
125,898 $3.89 Million
Q1 2021

May 12, 2021

BUY
$37.62 - $60.41 $5.06 Million - $8.13 Million
134,584 New
134,584 $5.87 Million

Others Institutions Holding SBTX

About Silverback Therapeutics, Inc.


  • Ticker SBTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,473,800
  • Description
  • Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...
More about SBTX
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.